Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRYK0X)

• DTT Name: Interleukin-1 beta (IL1B) DTT Info
• Gene Name: IL1B

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Canakinumab	DM8HLO5	Autosomal dominant familial periodic fever		Approved	[1]
Gallium nitrate	DMF9O6B	Hypercalcaemia	5B91.0	Approved	[2]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[3]
Rilonacept	DMGLUQS	Arthritis	FA20	Approved	[4]
Diacerein	DMN2Q5I	N. A.	N. A.	Phase 4	[5]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XOMA 052	DMOKQV7	Type-2 diabetes	5A11	Phase 3	[6]
ABT-981	DM6PTIX	Osteoarthritis	FA00-FA05	Phase 2	[7]
AC-201	DMB0TNL	Type-2 diabetes	5A11	Phase 2	[8]
LY-2189102	DMU81BH	Cardiovascular disease	BA00-BE2Z	Phase 2	[9]
CYT-013-IL1bQb	DMNICD4	Inflammation	1A00-CA43.1	Phase 1	[10]
TT-301	DM4QV8Y	Alzheimer disease	8A20	Phase 1	[11]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDP-484	DMJTB4E	Immune System disease	4A01-4B41	Discontinued in Phase 1/2	[12]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Celastrol	DMWQIJX	Motor neurone disease	8B60	Preclinical	[13]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DVD-Ig	DMWF9GQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]

References

• [1] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [2] Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
• [3] Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
• [4] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [5] Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
• [6] Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
• [7] Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
• [11] A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.
• [12] Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334.
• [13] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.